NCT02336386

CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma

Study of Cyclophosphamide，Liposome Doxorubicin Dexamethasone（CDD) Plus Bortezomib Compared With CDD in the Relapsed or Refractory Multiple Myeloma Combined With Extramedullary Plasmacytoma Patients

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Beijing Chao Yang Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether Cyclophosphamide, Liposome doxorubicin and Dexamethasone（CDD) Plus Bortezomib might have effective in extramedullary plasmacytoma.

Conditions

• Extramedullary Plasmacytoma

Interventions

Type	Name	Description
DRUG	CDD	Chemotherapy
DRUG	CDD Plus Bortezomib	Chemotherapy plus Proteasome Inhibitors

Timeline

• Start date: 2014-12-01
• Primary completion: 2016-12-01
• Completion: 2016-12-01
• First posted: 2015-01-13
• Last updated: 2015-01-13

Locations

1 site across 1 country: China